Japan generics approvals set to up pressure on Zithromax, Valtrex
This article was originally published in Scrip
The latest batch approval of generic drugs in Japan has attracted a large number of entrants for two molecules being opened up to their first such competition in the country, the oral macrolide antibiotic azithromycin (Pfizer's Zithromax) and the antiviral valaciclovir (GlaxoSmithKline's Valtrex).
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.